According to BCC Research, HAI treatments to increase from nearly $17.1 billion in 2015 to $23 billion by 2020

Share Article

According to the new report from BCC Research, the global market for selected healthcare-acquired infection (HAI) treatments was valued at nearly $15.2 billion in 2014. This market is expected to increase from nearly $17.1 billion in 2015 to $23 billion by 2020.

The global market for selected healthcare-acquired infection (HAI) treatments is expected to reach $23 billion by 2020

Based on Centers for Disease Control (CDC) prevalence survey released in March 2014, approximately 1 in 25 hospital patients had at least one healthcare-acquired infection (HAI). There were an estimated 722,000 HAI in U.S. acute care hospitals alone in 2011, with approximately 75,000 hospital patients with HAI dying during their hospitalizations. Additionally, more than half of all HAI occurred outside of the intensive care unit. BCC Research expects the global market for selected HAI treatments to increase from nearly $17.1 billion in 2015 to $23 billion by 2020, with a compound annual growth rate (CAGR) of 6.1% from 2015 to 2020.

Considerable resources have been devoted to reducing HAI in developed countries. Healthcare institutions are developing education on prevention for all areas of personnel, manufacturers continue to develop new products that specifically address HAI, pharmaceutical companies are pursuing new or reformulated antibiotic and antiviral medications to avert resistance, and healthcare personnel are vigorously pursuing infection control techniques that have been shown to reduce HAI.

“HAI infection rates are stabilizing and in some cases decreasing in the U.S. and some Western European countries partly due to increased control efforts by healthcare professionals and the availability of devices with specialized coatings to help avert infections,” says BCC Research analyst Peggy Lehr. “America currently holds approximately 42% of the global market for HAI products, but that leadership position is predicted to shrink to 40% by 2020 with the rise of Asian markets, particularly India and China.”

Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products (HLC092C) is a valuable tool for anyone assessing the HAI market and attempting to devise a strategy to successfully compete in this market. The report will benefit business planners, acquisition specialists, licensing strategists, product managers, market research analysts, investing consultants and others interested in the HAI market, its products, its participants and its future.

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at steven.cumming(at)bccresearch(dot)com.

About BCC Research
BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years we've helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key market participants. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Recently selected as the world’s greatest market research company, BCC Research is a unit of Eli Global, LLC. Visit our website at http://www.bccresearch.com. Contact us: (+1) 781-489-7301 (U.S. Eastern time), or email information(at)bccresearch(dot)com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Steven Cumming
BCC Research
+1 (781) 489-7301 Ext: 632
Email >
@bccresearch
Follow >
Visit website